Author | Year | Type of study | Study agent | Total number of patients | Number with colonic CD | End point | Main findings | p Value (for colonic vs other sites unless stated) | Conclusion |
---|---|---|---|---|---|---|---|---|---|
Sandborn et al163 | 2011 | RCT | Certolizumab pegol (CZP) | 338 | 120 | Week 6 remission (CDAI ≤150) | 23/63 (36.5%) CZP vs 10/57 (17.5%) placebo | 0.052 (colon vs other locations); 0.034 (active vs placebo) | Probable efficacy in colonic disease |
Arnott et al164 | 2003 | Cohort | Infliximab | 74 | 26 | Week 4 response (fall in HBI by >3) | 23/26 (88%) response in colonic vs 6/11 (54%) in ileal | 0.042 | Better efficacy in colonic than ileal |
Laharie et al165 | 2005 | Cohort | Infliximab | 44 | 18 | Week 8 response (fall in CDAI by ≥100) | 83.3% colonic CD vs 50% ileal/ileocolonic | 0.03 | Better efficacy in colonic than combined ileal/ileocolonic |
Vermeire et al166 | 2002 | Cohort | Infliximab | 240 | 89 | Week 4 (luminal) or week 10 (fistulising) response (fall in CDAI by ≥70 or 50% decrease in draining fistulae | 81% response colonic CD vs 55% ileal CD vs 74% ileocolonic OR 1.905, 95% CI 1.010 to 3.597 | 0.046 | Better efficacy in colonic than combined ileal/ileocolonic. Remission also more likely in isolated colonic (p=0.019) |
Dupont-Lucas et al167 | 2016 | Cohort | Infliximab | 248 (children) | 63 | Loss of response to maintenance therapy (moderate or severe global assessment requiring cessation of therapy) | Colonic 25/54 (46%) responders or remitters vs ileal/ileocolonic 148/185 (80%). HR 2.72 (95% CI 1.30 to 5.71) for loss of response in isolated colonic CD vs other sites | 0.008 | Isolated colonic disease more likely to lose response |
Cohen et al168 | 2012 | Cohort | Adalimumab | 75 | 15 | Time to dose escalation | 13.2 weeks for colonic vs 34.6 weeks for other sites | 0.0062 | Isolated colonic disease required earlier dose escalation |
Sandborn et al169 | 2013 | RCT | Vedolizumab | 1115 | 316 (273 active, 43 placebo) Subgroup analysis based on 62 active and 43 placebo | Remission (CDAI ≤150) at week 6 over placebo, response (CDAI fall ≥100) week 6 | Remission difference from placebo: 5.9% for colonic vs 6.7% for ileal vs 8.9% for ileocolonic Response: 10.6% for colonic vs minus 10.4% for ileal vs 7.1% for ileocolonic | 0.30 remission 0.23 response | No difference between isolated colonic and other Crohn's for induction with vedolizumab |
Sandborn et al169 | 2013 | RCT | Vedolizumab | 461 | 117 | Remission at week 52 over placebo | Remission 8 weekly vedolizumab: 18.9% difference from placebo for colonic vs 11.8% for ileal vs 19.9% for ileocolonic Remission 4 weekly vedolizumab: 12.7% for colonic vs 25.4% for ileal vs 12% for ileocolonic | 0.11 0.19 | No difference between isolated colonic and other Crohn's for maintenance with vedolizumab |
CD, Crohn's disease; HBI, Harvey Brashaw Index.